Search Results - "Neelapu, S.S"
-
1
Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling
Published in Cytotherapy (Oxford, England) (01-05-2017)Get full text
Journal Article -
2
Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines
Published in Vaccine (18-04-2011)“…Abstract Our laboratory previously described the strategy of fusing chemokine receptor ligands to antigens in order to generate immunogenic DNA vaccines. In…”
Get full text
Journal Article -
3
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Published in The New England journal of medicine (28-12-2017)“…In 101 patients with refractory large B-cell lymphoma, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel) resulted in an…”
Get full text
Journal Article -
4
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR ASPERGILLOSIS
Published in Cytotherapy (Oxford, England) (01-06-2024)“…Invasive aspergillosis (IA) is a common and deadly mold infection in immunocompromised patients. As morbidity and mortality of IA are primarily driven by poor…”
Get full text
Journal Article -
5
Bridging Radiotherapy prior to Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma
Published in International journal of radiation oncology, biology, physics (01-10-2024)“…Brexucabtagene autoleucel (BA) is a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy approved in the treatment of relapsed/refractory (r/r)…”
Get full text
Journal Article -
6
Outcomes and Toxicities in Patients with Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract
Published in International journal of radiation oncology, biology, physics (01-10-2023)“…Diffuse large B-cell lymphoma (DLBCL) involving the gastrointestinal (GI) tract is rare and long-term outcomes are not well defined. Combined modality therapy…”
Get full text
Journal Article -
7
Characterization of Lymphopenia during Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Patients with Aggressive B Cell Lymphomas
Published in International journal of radiation oncology, biology, physics (01-10-2023)“…Bridging RT (bRT) may be used as a strategy for disease control in patients with relapsed/refractory aggressive B cell lymphoma treated with anti-CD19-directed…”
Get full text
Journal Article -
8
Ultra Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung
Published in International journal of radiation oncology, biology, physics (01-10-2023)“…Definitive radiation treatment (RT) for extranodal marginal zone lymphoma (ENMZL) of mucosal associated lymphoid tissue historically involves treatment to…”
Get full text
Journal Article -
9
Outcomes with Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Pts with Aggressive B Cell Lymphomas
Published in International journal of radiation oncology, biology, physics (01-10-2023)“…Select patient (pts) with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen…”
Get full text
Journal Article -
10
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
Published in Leukemia (01-09-2013)“…Lenalidomide–rituximab therapy is effective in grade 1–2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL),…”
Get full text
Journal Article -
11
-
12
-
13
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma
Published in Oncogene (08-12-2011)“…Successful treatment of diffuse large B-cell lymphoma (DLBCL) is frequently hindered by the development of resistance to conventional chemotherapy resulting in…”
Get full text
Journal Article -
14
-
15
-
16
-
17
Prognostic Value of Disease Location in Secondary Central Nervous System Diffuse Large B-Cell Lymphoma
Published in International journal of radiation oncology, biology, physics (01-11-2020)Get full text
Journal Article -
18
Concurrent Radiation Therapy With the Antibody-Drug Conjugates Brentuximab Vedotin and Polatuzumab Vedotin
Published in International journal of radiation oncology, biology, physics (01-11-2021)“…Brentuximab vedotin (BV) and polatuzumab vedotin (PV) are antibody-drug conjugates targeting CD30 and CD79B, respectively, approved for the treatment of select…”
Get full text
Journal Article -
19
-
20
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy
Published in Haematologica (Roma) (01-05-2021)Get full text
Journal Article